These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19581304)

  • 21. The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis.
    Loo TW; Clarke DM
    J Biol Chem; 2000 Feb; 275(8):5253-6. PubMed ID: 10681495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2004 Apr; 279(18):18232-8. PubMed ID: 14749322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
    De Rosa MF; Ackerley C; Wang B; Ito S; Clarke DM; Lingwood C
    J Biol Chem; 2008 Feb; 283(8):4501-11. PubMed ID: 18003606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein.
    Mandal D; Moitra K; Ghosh D; Xia D; Dey S
    Biochemistry; 2012 Apr; 51(13):2852-66. PubMed ID: 22360349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drug-binding site.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2003 Jun; 278(23):20449-52. PubMed ID: 12711602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Locking intracellular helices 2 and 3 together inactivates human P-glycoprotein.
    Loo TW; Clarke DM
    J Biol Chem; 2014 Jan; 289(1):229-36. PubMed ID: 24275649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter.
    Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
    Pharm Res; 1998 Jul; 15(7):1001-6. PubMed ID: 9688051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human P-glycoprotein contains a greasy ball-and-socket joint at the second transmission interface.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2013 Jul; 288(28):20326-33. PubMed ID: 23733192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The W232R suppressor mutation promotes maturation of a truncation mutant lacking both nucleotide-binding domains and restores interdomain assembly and activity of P-glycoprotein processing mutants.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2011 Feb; 50(5):672-85. PubMed ID: 21182301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug rescue distinguishes between different structural models of human P-glycoprotein.
    Loo TW; Clarke DM
    Biochemistry; 2013 Oct; 52(41):7167-9. PubMed ID: 24083983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein.
    Chufan EE; Kapoor K; Ambudkar SV
    Biochem Pharmacol; 2016 Feb; 101():40-53. PubMed ID: 26686578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutagenesis of transmembrane domain 11 of P-glycoprotein by alanine scanning.
    Hanna M; Brault M; Kwan T; Kast C; Gros P
    Biochemistry; 1996 Mar; 35(11):3625-35. PubMed ID: 8639515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence.
    Kast C; Canfield V; Levenson R; Gros P
    J Biol Chem; 1996 Apr; 271(16):9240-8. PubMed ID: 8621583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiol-reactive drug substrates of human P-glycoprotein label the same sites to activate ATPase activity in membranes or dodecyl maltoside detergent micelles.
    Loo TW; Clarke DM
    Biochem Biophys Res Commun; 2017 Jul; 488(4):573-577. PubMed ID: 28533092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dileucine motif at the COOH terminus of human multidrug resistance P-glycoprotein is important for folding but not activity.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2005 Jan; 280(4):2522-8. PubMed ID: 15542593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2007 Aug; 46(32):9328-36. PubMed ID: 17636884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Both ATP sites of human P-glycoprotein are essential but not symmetric.
    Hrycyna CA; Ramachandra M; Germann UA; Cheng PW; Pastan I; Gottesman MM
    Biochemistry; 1999 Oct; 38(42):13887-99. PubMed ID: 10529234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335).
    Chen KG; Lacayo NJ; Durán GE; Cohen D; Sikic BI
    Mol Pharmacol; 2000 Apr; 57(4):769-77. PubMed ID: 10727524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2.
    Zhou Y; Gottesman MM; Pastan I
    Arch Biochem Biophys; 1999 Jul; 367(1):74-80. PubMed ID: 10375401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insights into the P-glycoprotein-mediated effluxes of rhodamines.
    Loetchutinat C; Saengkhae C; Marbeuf-Gueye C; Garnier-Suillerot A
    Eur J Biochem; 2003 Feb; 270(3):476-85. PubMed ID: 12542697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.